Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Researchers sought to examine the relationship between depressive symptoms and pain in U.S. veterans 50 years of age or older.
Cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder.
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.